To determine if the engineered destabilized 3'UTR ERBB2 constructs packaged into the IO nanocage (22–24, 28, 29) inhibit the primary tumor, we implanted 25 NSG mice with five million NCI-H1975 cells into the flank; after 35 days of tumor engraftment, we randomized the mice into five mice per cage on the day 36 (Supplementary Figure 1A). This evidence concerns the gene ERBB2 and neoplasm.